PCN24 - Duration of Treatment and Economic Burden in Patients with Anaplastic Lymphoma Kinase Positive (ALK+) Non–Small Cell Lung Cancer (NSCLC) Receiving Second-Line Alk Inhibitors. - Lin, HM; Hou, P; Huang, H; Desai, A; Jahanzeb, M (Value in Health, 2018)